Is ritexitinib available in China?

Ritlecitinib is a highly selective oral Janus kinase (JAK) inhibitor Agent, mainly acting on JAK3 and TEC family kinases, suitable for the treatment of alopecia areata (Alopecia Areata), an autoimmune disease. Alopecia areata occurs when the immune system mistakenly attacks hair follicles, causing hair to fall out. Riterxitinib inhibits the activity of the JAK-STAT signaling pathway in the immune system, reduces the attack of T cells on hair follicles, protects hair follicle function, and promotes hair regeneration and growth.

In clinical trials, ritexitinib showed significant efficacy in patients with moderate to severe alopecia areata. Research data shows that after 24 weeks of treatment, many patients have significantly improved hair coverage and are well tolerated. Common adverse reactions include upper respiratory tract infection, headache and gastrointestinal discomfort, most of which are mild to moderate and controllable.

Currently, ritexitinib is already on the market in China, but has not yet been included in the medical insurance catalog. Therefore, patients need to bear the cost when purchasing drugs in the country, and the price is about more than 3,000 yuan. Specific prices will vary by hospital and region, and patients are advised to consult their local hospital pharmacy for detailed information before purchasing.

Abroad, the original drug of ritexitinib mainly has a European version, which is more expensive, about more than 10,000 yuan. For patients in need, overseas channels also provide more economical options, such as the Lao version of generic drugs. The price is relatively cheap, about more than a thousand yuan, and the drug ingredients are basically the same as the original drugs.

The launch of ritixitinib provides a new treatment option for patients with alopecia areata, especially those who have responded poorly to other treatments. Although the price of the drug is still at a high level in China, its significant efficacy makes it one of the important choices for patients to regain their hair. In the future, with the accumulation of more data and application experience, it is expected to be further promoted and its affordability will be improved.